Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 4:2021:9914787.
doi: 10.1155/2021/9914787. eCollection 2021.

Role of Folic Acid Drugs in the Treatment with Antithrombotic and Anticoagulant Drugs for Patients with Cardiovascular Diseases Based on the Analysis of Virtual Reality Medical Data

Aiguo Zhang  1 , Jing Wang  1 , Qiang Jing  1
Affiliations

Role of Folic Acid Drugs in the Treatment with Antithrombotic and Anticoagulant Drugs for Patients with Cardiovascular Diseases Based on the Analysis of Virtual Reality Medical Data

Aiguo Zhang et al. J Healthc Eng. .

Retraction in

Abstract

In recent years, with the continuous progress and development of science and technology and the increasing maturity of medical technology, the incidence of cardiovascular diseases has gradually increased with the age of the population. In the case of cardiovascular disease, proper anticoagulant therapy can effectively prevent bleeding in the occurrence of events, so a more effective treatment of cardiovascular disease is considered a difficult problem to overcome. Therefore, this article proposes the role of folic acid drugs based on virtual reality medical data analysis in the treatment of cardiovascular disease patients with antithrombotic and anticoagulant drugs, in order to improve providing help for cardiovascular disease. This study selected patients with cardiovascular disease who were admitted to the hospital and extracted 100 patients with complete data and a one-year follow-up period, covering the overall status of the patients' cardiovascular risk factors, cardiovascular disease degree, and the occurrence of major cardiovascular adverse events. During the follow-up period, we analyzed the specific status of major cardiovascular adverse events and the occurrence of bleeding events and compared and analyzed the effects of folic acid drugs on the treatment with antithrombotic and anticoagulant drugs in patients with cardiovascular disease. Experiments have proved that the differences in the degree of cardiovascular stenosis and the number of cardiovascular disease vessels in the four groups are statistically significant (P < 0.01). The degree of cardiovascular stenosis in group D was lighter than that in groups A, B, and C, and the number of cardiovascular lesions was also less than that in groups A, B, and C. The differences were statistically significant (P < 0.05). This indicates that folic acid can effectively treat cardiovascular stenosis, prevent cardiovascular disease, and then treat patients with cardiovascular disease with antithrombotic and anticoagulant drugs. It provides an important basis for accurate clinical diagnosis and treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest regarding the publication of this study.

Figures

Figure 1
Figure 1
Indicator reliability test analysis chart.
Figure 2
Figure 2
Cardiovascular disease risk factor analysis chart.
Figure 3
Figure 3
Analysis of the number of diseased vessels.
Figure 4
Figure 4
Multivariate logistic regression analysis chart of risk factors.
Figure 5
Figure 5
Analysis chart of the overall situation of major adverse cardiovascular events.
See this image and copyright information in PMC

References

    1. Fernández-Montero J. V., Barreiro P., De Mendoza C., Labarga P., Soriano V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. Journal of Viral Hepatitis. 2016;23(1):47–52. doi: 10.1111/jvh.12447. - DOI - PubMed
    1. Leone S., Prosperi M., Costarelli S., et al. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response. European Journal of Clinical Microbiology & Infectious Diseases. 2016;35(9):1511–1520. doi: 10.1007/s10096-016-2692-y. - DOI - PubMed
    1. Klingel R., Heibges A., Fassbender C. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. Clinical Research in Cardiology Supplements. 2017;12:38–43. doi: 10.1007/s11789-017-0082-3. - DOI - PMC - PubMed
    1. Joo H., Zhang P., Wang G. Cost of informal care for patients with cardiovascular disease or diabetes: current evidence and research challenges. Quality of Life Research. 2016;26(6):1–8. doi: 10.1007/s11136-016-1478-0. - DOI - PMC - PubMed
    1. Leiter L. A., Cefalu W. T., De Bruin T. W. A., et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes, Obesity and Metabolism. 2016;18(8):766–774. doi: 10.1111/dom.12666. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources